Brought to you by 
Amgen and Biovitrum sign license agreements
Sep 2003
Executive Summary
To strengthen its foothold in the area of metabolic diseases, Amgen licensed exclusive development and marketing rights in North and South America, the EU, Australia, and New Zealand to Biovitrum AB's (focuses on metabolic disorders) small-molecule 11beta-hydroxysteroid dehydrogenase 1 (HSD1) enzyme inhibitor platform. It will initially concentrate on developing BVT.3498, which is in Phase IIa clinical trials to treat Type II diabetes and related metabolic diseases. The deal also gives Biovitrum rights to some Amgen products.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Co-Promotion
- Intra-Biotech Deal
- Product or Technology Swap
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amgen and Biovitrum sign license agreements
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice